Tecovirimat

證據等級: L5

預測適應症: 10 個

Tecovirimat: From Smallpox to Vaccinia Virus Infection

One-Sentence Summary

Tecovirimat (TPOXX®) was approved for the treatment of symptomatic smallpox, and by extension has long been used off-label/under expanded access for vaccinia virus complications (e.g. progressive vaccinia, eczema vaccinatum). TxGNN's top-ranked prediction (hordeolum, score 99.66%) has zero supporting evidence and is mechanistically implausible for an orthopoxvirus-specific antiviral; among the ten candidates in this evidence pack, vaccinia (rank 5) is the only one with substantive, mechanistically coherent support — 3 clinical trials and 19 publications — and is therefore the indication evaluated below. Note: this same evidence base also contains signals that recent Phase 3 trials in mpox (a related but distinct clinical entity) were negative, so the strength of evidence differs sharply between "vaccinia infection/complications" and "mpox disease."

Quick Overview

Item	Content
Original Indication	Smallpox (per literature evidence within this pack; no Finland package-insert data available — Data Gap)
Predicted New Indication	Vaccinia (virus infection / vaccination complications)
TxGNN Prediction Score	99.62%
Evidence Level	L2
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action text is not available for tecovirimat in this evidence pack (Data Gap). Based on the literature evidence collected, tecovirimat inhibits the orthopoxvirus VP37 envelope-wrapping protein, blocking viral envelopment and cell-to-cell spread. This mechanism is shared across the entire orthopoxvirus genus — variola (smallpox), vaccinia, monkeypox/mpox, and cowpox — because VP37 is conserved among these related viruses.

Tecovirimat's original approval (smallpox/variola, via the FDA Animal Rule) and its predicted new use (vaccinia) are therefore genus-mates rather than distinct disease areas. In fact, tecovirimat has already been used for years under CDC IND / expanded-access protocols to treat vaccinia vaccination complications (progressive vaccinia, eczema vaccinatum) and vaccine-related adverse reactions — this is not a novel repurposing hypothesis so much as a confirmation of an existing, mechanistically-grounded use pattern that TxGNN independently recovered.

One important caveat surfaced by the evidence: the same drug, same mechanistic class, applied to mpox clinical disease rather than vaccinia-per-se, has recently produced negative Phase 3 results — the STOMP/A5418 trial (clade II mpox) showed no significant benefit on lesion healing, pain, or viral clearance and was stopped early for futility, and a DRC clade I Phase 3 also failed to show significant efficacy. This means the strength of "same mechanism, same virus genus" reasoning does not automatically transfer from vaccinia (where efficacy is established) to mpox (where recent controlled trials are negative) — these should be treated as two separate indications, not one.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04957485	Phase 2	Active, not recruiting	100	Randomized, placebo-controlled study of oral TPOXX (28 days BID) vs. placebo on JYNNEOS® vaccine immunogenicity — evaluates drug-vaccine interaction in orthopoxvirus-exposed populations.
NCT05380752	N/A (Expanded Access)	No longer available	N/A	Expanded-access protocol providing IV tecovirimat (10 mg/mL) to patients with confirmed/suspected orthopoxvirus infection or significant vaccinia adverse reactions from vaccination; real-world feasibility data only, not a controlled efficacy trial.
NCT05976100	Phase 1	Completed	90	Safety, tolerability and PK study of NIOCH-14 (a different orthopoxvirus antiviral, not tecovirimat) — indirect supporting evidence for the drug class only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32882158	2021	Review	Expert Rev Anti Infect Ther	Overview confirming tecovirimat's 2018 FDA approval for smallpox and rationale for expanded anti-orthopoxvirus (including vaccinia) applications.
37131608	2023	Review	bioRxiv	Reviews antivirals against monkeypox/orthopoxviruses; tecovirimat and brincidofovir are the two FDA-approved options.
35763248	2022	Review	Drugs	Prevention and treatment review noting tecovirimat as a stockpiled orthopoxvirus countermeasure alongside JYNNEOS vaccination.
36403582	2023	Review	Lancet	General monkeypox virus review situating tecovirimat within the Orthopoxvirus genus alongside vaccinia and variola.
39401235	2024	Review	JAMA	Clinical presentation/treatment review of mpox, covering diagnostic and treatment strategies including tecovirimat.
38801579	2024	Review	Adv Exp Med Biol	Reviews Poxviridae pneumonia complications historically linked to variola, relevant to orthopoxvirus disease severity context.
36130588	2022	Review	J Pharm Pharm Sci	Comprehensive monkeypox virology/treatment review including antiviral options.
36992234	2023	Case Report	Vaccines	Successful outcome using cidofovir, vaccinia immunoglobulin, and extended-course tecovirimat in an HIV patient with severe mpox.
37394761	2023	Case Report	J Med Virol	Severe soft-tissue mpox complication in HIV coinfection treated with IV vaccinia immunoglobulin and IV tecovirimat.
40210872	2025	Preclinical	Signal Transduct Target Ther	Notes that tecovirimat's clinical efficacy in recent trials has been "far from satisfactory," motivating new orthopoxvirus antiviral derivatives.

Finland Market Information

Tecovirimat currently holds no marketing authorization in Finland (market status: not marketed, 0 licenses on record). No dosage form or approved-indication text is available to summarize.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data were available in this evidence pack (all flagged as Data Gaps, including TFDA/Finland package insert — DG001, Blocking severity).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between tecovirimat's approved orthopoxvirus activity and vaccinia complications is well established (existing CDC IND/expanded-access use, L2 evidence with an active Phase 2 trial), supporting a guarded "yes" for vaccinia-specific use. However, recent negative Phase 3 mpox trials (STOMP/A5418, DRC clade I) show the same mechanism does not guarantee clinical benefit in the closely related mpox disease — this pack's other nine predicted indications (hordeolum, vibrio, Klebsiella, noma, HTLV-1 dermatitis, coinfection, Arterivirus, arbovirus, E. coli infection) are TxGNN score artifacts with no biological plausibility or evidence (L4–L5, Hold) and should not be pursued.

To proceed, the following is needed:

TFDA/Finland package insert (warnings, contraindications, DDI) — currently a Blocking data gap (DG001)
Formal DrugBank-sourced mechanism-of-action confirmation (DG002)
A study protocol that explicitly separates "vaccinia infection/vaccination complications" from "mpox clinical disease," given their diverging trial outcomes
Local regulatory pathway assessment for Finland, where the drug is currently unmarketed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.